
Advancements in ROS1-Positive Non-Small Cell Lung Cancer A recent article from CURE Today highlights the progress being made in targeted therapies for this rare subtype of lung cancer, which affects around 1-2% of patients. Our West family is proud to be at the forefront of this critical work, where Dr. Jason Porter and his team… Read more »